AbbVie: Risankizumab Recommended For EU Approval For Moderately-Severely Active Ulcerative Colitis
31/5 08:45
(RTTNews) - AbbVie Inc. (ABBV) announced Friday that Friday that Risankizumab (SKYRIZI) has been recommended for European Union approval for the treatment of adults with moderately to severely active Ulcerative Colitis or UC....